Regeneron (REGN) Tops Q3 EPS by $1.23, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Regeneron Reports Third Quarter 2020 Financial and Operating Results
November 5, 2020 6:30 AM ESTTARRYTOWN, N.Y., Nov. 5, 2020 /PRNewswire/ --
Third quarter 2020 revenues increased 32% to $2.29 billion versus third quarter 2019(4) Third quarter 2020 EYLEA® U.S. net sales increased 11% to $1.32 billion versus third quarter 2019 Third quarter 2020 Dupixent® global net sales(2), which are recorded by Sanofi, increased 69% to $1.07 billion versus third quarter 2019 Third quarter 2020 GAAP diluted EPS was $7.39 and non-GAAP diluted EPS(1) was $8.36 REGN-COV2 trial in the COVID-19 outpatient setting met primary and key secondary endpoints FDA accepted for priority review Libtayo® (cemiplimab-rwlc) for both advanced... More